Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Monday, November 13th, MarketBeat reports. They presently have a $11.00 target price on the stock, down from their prior target price of $11.48. J P Morgan Chase & Co’s price target would indicate a potential downside of 27.92% from the company’s current price.
A number of other brokerages have also recently issued reports on TEVA. Jefferies Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Tuesday, July 25th. Vetr upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research note on Monday, July 24th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Royal Bank Of Canada restated an “outperform” rating and set a $37.00 price objective (down from $38.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, July 17th. Finally, Mizuho restated a “hold” rating and set a $30.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Wednesday, August 2nd. Seven research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $21.65.
Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.44 on Monday, hitting $15.26. The company had a trading volume of 26,517,515 shares, compared to its average volume of 25,609,576. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market cap of $15,057.12, a PE ratio of 3.42 and a beta of 0.55.
TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by J P Morgan Chase & Co to “Underweight”” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-stock-rating-lowered-by-j-p-morgan-chase-co/1781217.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.